title: Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and to project HCV incidence rates.
abstract: Surveillance for hepatitis C virus (HCV) is limited by the challenge of differentiating between acute and chronic infections. In this study, we evaluate a cross-sectional testing strategy that identifies individuals with acute HCV infection and we estimate HCV incidence. Anti-HCV-negative persons from four populations with various risks, i.e., blood donors, Veterans Administration (VA) patients, young injection drug users (IDU), and older IDU, were screened for HCV RNA by minipool or individual sample nucleic acid testing (NAT). The number of detected viremic seronegative infections was combined with the duration of the preseroconversion NAT-positive window period (derived from analysis of frequent serial samples from plasma donors followed from NAT detection to seroconversion) to estimate annual HCV incidence rates. Projected incidence rates were compared to observed incidence rates. Projected HCV incidence rates per 100 person-years were 0.0042 (95% confidence interval [95% CI], 0.0025 to 0.007) for blood donors, 0.86 (95% CI, 0.02 to 0.71) for VA patients, 39.8 (95% CI, 25.9 to 53.7) for young IDU, and 53.7 (95% CI, 23.4 to 108.8) for older IDU. Projected rates were most similar to observed incidence rates for young IDU (33.4; 95% CI, 28.0 to 39.9). This study demonstrates the value of applying a cross-sectional screening strategy to detect acute HCV infections and to estimate HCV incidence.
authors.affiliation: University of California, San Francisco, California, USA.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Page-Shafer
authors.forename: Brandee L
authors.initials: BL
authors.lastname: Pappalardo
authors.forename: Leslie H
authors.initials: LH
authors.lastname: Tobler
authors.forename: Bruce H
authors.initials: BH
authors.lastname: Phelps
authors.forename: Brian R
authors.initials: BR
authors.lastname: Edlin
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Moss
authors.forename: Teresa L
authors.initials: TL
authors.lastname: Wright
authors.forename: David J
authors.initials: DJ
authors.lastname: Wright
authors.forename: Thomas R
authors.initials: TR
authors.lastname: O'Brien
authors.forename: Sally
authors.initials: S
authors.lastname: Caglioti
authors.forename: Michael P
authors.initials: MP
authors.lastname: Busch
mesh_terms: D000328:Adult; D000367:Age Factors; D001782:Blood Donors; D003430:Cross-Sectional Studies; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000175:diagnosis* / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D015819:Substance Abuse, Intravenous; D013997:Time Factors; D014728:Veterans
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral